Indium (In111) Chloride Drn 4901 Curium Netherlands B.V.

Indium-111 chloride, the active ingredient in Indium (In111) Chloride Drn 4901 Curium Netherlands B.V., is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed to image infection, inflammation, tumor and bone marrow activity in patients undergoing diagnostic scintigraphy.

GNH USA supplies Indium (In111) Chloride Drn 4901 Curium Netherlands B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Indium-111 chloride is used in nuclear medicine to visualize sites of infection, inflammation, tumor activity and bone marrow function.

- Infection and inflammation: enables detection of active infectious or inflammatory foci through labeled leukocyte scintigraphy. - Tumor imaging: highlights malignant lesions by accumulating in tumor‑associated cells for diagnostic assessment. - Bone marrow imaging: visualizes marrow distribution and function, assisting in evaluation of hematologic disorders.

Administration of Indium-111 chloride may be associated with adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema. - Nausea or mild vomiting. - Transient headache. - Mild hypotension. - Flushing or warmth sensation. - Minor allergic skin rash.

Serious or Rare Side Effects: - Anaphylactic reaction. - Severe hypotension or cardiovascular collapse. - Radiation‑induced skin injury at injection site. - Bone marrow suppression. - Acute hemolysis. - Severe infection due to contaminated preparation.

Prior to use, clinicians should consider several safety measures to minimize risks associated with Indium-111 chloride. - Pregnancy: avoid use unless essential, as fetal radiation exposure is unknown. - Breastfeeding: discontinue breastfeeding or choose alternative, due to potential radiotracer transfer. - Renal impairment: adjust handling, as excretion may be reduced. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Verify labeling: confirm patient identity and correct radiotracer activity before injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 chloride can interact with other agents that affect radiotracer distribution or radiation safety.

Major Interactions (Avoid): - Concurrent administration of other radiopharmaceuticals that emit similar gamma energies, which may cause image overlap. - High‑dose iodine or perchlorate therapy, which can alter cellular uptake of the tracer. - Chelating agents (e.g., EDTA) that may bind the indium ion and reduce labeling efficiency.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs that affect leukocyte function, potentially altering tracer localization. - Anticoagulants, which may increase risk of bleeding at injection site. - Contrast agents used in CT, which may interfere with image interpretation if administered closely in time.